Welcome to our dedicated page for Roivant Sciences news (Ticker: ROIV), a resource for investors and traders seeking the latest updates and insights on Roivant Sciences stock.
Roivant Sciences Ltd. (Nasdaq: ROIV) generates a steady flow of news as a biopharmaceutical company focused on developing and commercializing medicines for autoimmune, inflammatory and cardiopulmonary diseases. Company updates frequently center on its late-stage clinical pipeline, including brepocitinib, IMVT-1402, batoclimab and mosliciguat, as well as developments at its subsidiaries Priovant Therapeutics, Immunovant, Pulmovant and Genevant.
Investors following ROIV news can expect detailed coverage of clinical milestones, such as Phase 3 and Phase 2 trial readouts, proof-of-concept data and regulatory filing plans. Recent communications have highlighted positive Phase 3 VALOR results for brepocitinib in dermatomyositis, rapid enrollment in non-infectious uveitis and cutaneous sarcoidosis studies, and six-month off-treatment remission data in Graves’ disease from Immunovant’s batoclimab program. Roivant also issues news about potentially registrational trials for IMVT-1402 across several autoimmune indications and ongoing development of mosliciguat in pulmonary hypertension associated with interstitial lung disease.
Roivant’s news flow also includes quarterly and annual financial results, updates on research and development and general and administrative expenses, and information on capital allocation decisions such as common share repurchase programs. In addition, Genevant-related news may cover progress in lipid nanoparticle intellectual property litigation involving companies such as Moderna and Pfizer/BioNTech, as described in Roivant’s public updates.
This ROIV news page brings together press releases, clinical updates, financial disclosures and other company communications in one place. Readers can use it to monitor trial timelines, regulatory plans, subsidiary activities and financial reporting that Roivant discloses through its press releases and SEC filings.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.